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Abstract
Background: Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially
effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC)
patients at present do not benefit from this treatment.
The primary site of gefitinib metabolism is the liver, nevertheless tumor cell metabolism can significantly affect
treatment effectiveness.
Results: In this study, we investigated the intracellular metabolism of gefitinib in a panel of EGFR wild-type
gefitinib-sensitive and -resistant NSCLC cell lines, assessing the role of cytochrome P450 1A1 (CYP1A1) inhibition on
gefitinib efficacy. Our results indicate that there is a significant difference in drug metabolism between gefitinib-
sensitive and -resistant cell lines. Unexpectedly, only sensitive cells metabolized gefitinib, producing metabolites
which were detected both inside and outside the cells. As a consequence of gefitinib metabolism, the intracellular
level of gefitinib was markedly reduced after 12-24 h of treatment. Consistent with this observation, RT-PCR analysis
and EROD assay showed that mRNA and activity of CYP1A1 were present at significant levels and were induced by
gefitinib only in sensitive cells. Gefitinib metabolism was elevated in crowded cells, stimulated by exposure to
cigarette smoke extract and prevented by hypoxic condition. It is worth noting that the metabolism of gefitinib in
the sensitive cells is a consequence and not the cause of drug responsiveness, indeed treatment with a CYP1A1
inhibitor increased the efficacy of the drug because it prevented the fall in intracellular gefitinib level and
significantly enhanced the inhibition of EGFR autophosphorylation, MAPK and PI3K/AKT/mTOR signalling pathways
and cell proliferation.
Conclusion: Our findings suggest that gefitinib metabolism in lung cancer cells, elicited by CYP1A1 activity, might
represent an early assessment of gefitinib responsiveness in NSCLC cells lacking activating mutations. On the other
hand, in metabolizing cells, the inhibition of CYP1A1 might lead to increased local exposure to the active drug and
thus increase gefitinib potency.
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Background
Gefitinib is an orally active, selective EGFR TKI used in
the treatment of patients with advanced-NSCLC carrying
activating EGFR mutations [1]. In fact, it is well established
that gefitinib is more active in some patient subgroups,
such as Asians, females, never smokers and adenocarci-
noma histotypes which have a higher probability of har-
bouring activating mutations in the tyrosine kinase
domain, the most frequent being L858R in exon 21 and
Del (746-750) in exon 19 [1]. As a consequence most of
the NSCLCs containing wild-type EGFR receptor are
excluded and hence the role of gefitinib for the treatment
of NSCLC is limited. However, some studies have shown
that patients without mutations responded to gefitinib
with response rates reaching 6.6% [2,3]. In addition to can-
cer cell genomic determinants of sensitivity, some pharma-
cokinetic parameters may also play a role in the variable
response to gefitinib and other TKIs [4].
When administered at 250 mg/day, gefitinib is 60%
orally absorbed and 90% plasma protein-bound [5,6]. The
very high distribution volume of gefitinib (1400 litres)
clearly indicates that the drug is extensively distributed in
tissues such as liver, kidney, gastrointestinal tract, lung
and in tumors [7]. A tendency to accumulate in the lung
was observed with concentrations 10 times higher than in
plasma [8]. We have recently demonstrated in NSCLC cell
lines that the uptake of gefitinib is an essentially active
process leading to intracellular gefitinib concentrations
more than two hundred times higher than outside the
cells [9].
There are few data on gefitinib intracellular metabolism
in tumors, the majority of the available data concerns liver
metabolism. In vitro and in vivo studies indicate that in
the liver gefitinib is mainly metabolized by cytochrome
P450-dependent (CYP) activities, including CYP3A4,
CYP3A5 and CYP2D6 [10-12]. The main metabolic path-
way characterized by using human liver microsomes
include morpholine ring opening, O-demethylation of the
methoxy-substituent on the quinazoline ring structure and
oxidative defluorination of the halogenated phenyl group
[13,14].
A study investigating the contribution of individual
CYPs to gefitinib metabolism demonstrated that gefitinib
disappeared with similar clearance when incubated with
CYP3A4 or CYP2D6 enzymes, less efficiently with
CYP3A5 or CYP1A1, whereas CYP1A2 and CYP1B1 were
not involved in the metabolism of the drug [12]. Incuba-
tion with CYP3A4 and to a lesser extent CYP3A5, pro-
duced a similar range of metabolites as that produced by
liver microsomes [11], but the main plasma metabolite,
the O-desmethyl derivative present at plasma concentra-
tions similar to gefitinib [10], was formed predominantly
through the CYP2D6 enzyme.
CYP1A1 is one of the three members of the CYP1
family mainly expressed in extra-hepatic tissue, involved
in the metabolism of a large number of xenobiotics as
well as a small number of endogenous substrates [15].
Being expressed at a significant level in human lung
[16], it might play a role in the metabolism of gefitinib
by lung tumor cells and its activity might be involved in
the variability of the drug response.
In experiments using lung microsomes, CYP1A1 was
shown to produce significant amounts of the para-
hydroxyaniline metabolite derived from oxidative
defluorination of gefitinib. Hydroxyaniline metabolites
produced by CYP1A1 can be oxidized to reactive qui-
none-imine derivatives that form adducts with nucleo-
philic groups of macromolecules or GSH and may be
related to clinically relevant hepatotoxicity or interstitial
lung disease [8].
Both mRNA and protein CYP1A1 levels in human
lung are greatly induced by tobacco smoke [17] and it
has been reported that lung microsomes from smokers
may generate 12 times more gefitinib-derived reactive
metabolites as compared to non-smokers [8].
The present study was designed to investigate gefitinib
metabolism in a panel of EGFR wild-type NSCLC cell
lines either sensitive or resistant to gefitinib. Our objec-
tive was to define a possible potential role of gefitinib
metabolism in early evaluation of tumor response to
gefitinib, to analyze conditions or factors that can alter
tumor gefitinib metabolism and to test the effect of
CYP1A1 inhibition on gefitinib efficacy.
Methods
Cell culture
The human NSCLC cell lines H322, Calu-3, H292,
H460, H1299, A549, Calu-1 and SKLU-1 were cultured
as recommended. Cell lines obtained from American
Type Culture Collection (Manassas, VA, USA) were
immediately expanded and frozen. Every four months all
the cell lines were restarted from a frozen vial of the
same batch of cells and no additional authentication was
done in our laboratory. All cells were maintained under
standard cell culture conditions at 37°C in a water-satu-
rated atmosphere of 5% CO2 in air. As previously
reported [18] cells showing in proliferation assays IC50
for gefitinib < 1 μM were considered sensitive (H322,
H292, Calu-3) and cell lines with IC50 > 8 μM (H460,
H1299, A549, Calu-1 and SKLU-1) were considered
resistant.
Hypoxia
Hypoxic conditions (0.5%O2) were established by placing
the cells in a tissue culture incubator (Binder GmbH,
Tuttlingen, Germany) with controlled O2 levels.
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Preparation of cigarette smoke extract (CSE)
CSE preparation was made according to Carp and Janoff
[19], with slight modifications. Briefly, one cigarette with-
out filter was combusted using a modified syringe-driven
apparatus and the smoke was bubbled through 50 ml of
serum-free cell culture medium. This solution, considered
to be 100% CSE, was filtered diluted with medium and
applied to cell cultures within 30 min of preparation.
CYP1A1 genotyping
Genomic DNA was isolated using a PureGene DNA puri-
fication system (GENTRA SYSTEMS, Minneapolis, MN)
and both the rs 4646903 (3798 T > C, variant allele
CYP1A1*2A) and the rs 1048943 (2454 A > G, variant
allele CYP1A1*2C) polymorphisms of the CYP1A1 gene
that were characterized according to previously published
methods, with minimal changes [20,21]. All the tested cell
lines carried a wild type homozygous genotype for both
the polymorphisms.
Drug treatment
Gefitinib (ZD1839/Iressa) and metabolites [morpholine
ring-opening (M537194, M1), oxidative defluorinated
(M387783, M2) and O-desmethyl (M523595, M3) deriva-
tives] were kindly provided by AstraZeneca. a-naphthofla-
vone (a-NAP) was from Sigma Aldrich (St. Louis, MO,
USA).
Cetuximab, erlotinib and lapatinib were from inpatient
pharmacy. RAD001 and NVP-BEZ235 were provided by
Novartis Institutes for BioMedical Research (Basel, Swit-
zerland). Wortmannin, PD98059 and U0126 were from
Sigma-Aldrich (St. Louis, MO).
Uptake measurements
[3H]gefitinib uptake by cells was determined as
described recently [9].
Liquid chromatography tandem mass spectrometry (LC-
MS/MS)
For LC-MS/MS analysis, the medium samples were trea-
ted with ethyl acetate, dried under nitrogen and refilled
with methanol and aqueous formic acid (0.1 M), while the
ethanolic extracts were diluted with aqueous formic acid
(0.1 M).
LC analyses were carried out with an Agilent HP 1100
pump coupled with a API4000 triple-quadrupole mass
spectrometer (Sciex, Concord, Canada) equipped with a
TurboIonSprayTM interface and configured in Selected
Reaction Monitoring (SRM) mode. Chromatography was
performed on a Synergi Hydro-RP column (5 × 2.0 mm i.
d., 2 μm; Phenomenex) using variable proportions of 10
mM aqueous formic acid and methanol/acetonitrile (95/5,
v/v) mixture as the mobile phase.
The analytes were ionized in positive ion mode and
the following SRM transitions were monitored: m/z 447
([M+H]+) ® 128 for Gefitinib; m/z 421 ([M+H]+) ®
320 for Metabolite 1; m/z 445 ([M+H]+) ® 128 for
Metabolite 2; m/z 433 ([M+H]+) ® 128 for Metabolite
3 and m/z 394 ([M+H]+) ® 336 for Internal Standard.
Erlotinib was used as Internal Standard.
Determination of cell growth
Cell number and viability were evaluated by cell count-
ing, crystal violet staining and MTT colorimetric assay
as previously described [18].
Western blot analysis
Procedures for protein extraction, solubilization, and
protein analysis by 1-D PAGE are described elsewhere
[22]. Anti-EGFR, anti-phospho-EGFR (tyr1068), anti-
phospho-p44/42 MAPK, anti-p44/42 MAPK, anti-phos-
pho-AKT (Ser473), anti-AKT and anti-actin were from
Cell Signaling Technology (Beverly, MA, USA).
Real-Time RT-PCR
Total RNA was isolated by the TRIzol® reagent (Invitro-
gen, Carlsbad, CA, USA) and reverse-transcribed as pre-
viously described [23]. The transcript levels of CYP1A1,
CYP1A2, CYP2D6, CYP3A4 and CYP3A5 genes were
assessed by Real-Time qRT-PCR on an iCycler iQ Multi-
color RealTime PCR Detection System (Bio-Rad, Hercules,
CA, USA). Primers and probes included: CYP1A1-F (5’-
TCCAAGAGTCCACCCTTCC-3’), CYP1A1-R (5’-AAG-
CATGATCAGTGTAGGGATCT-3’), CYP1A1-probe (5’-
FAM CAGCCACC 3’DQ); CYP1A2-F (5’-GGCTTCTA-
CATCCCCAAGAA-3’), CYP1A2-R (5’-CAGCTCTGGG
TCATGGTTG-3’), CYP1A2-probe (5’-FAM CAGTGGCA
3’DQ); CYP2D6-F (5’-CTTCCAAAAGGCTTTCCTGA-
3’), CYP2D6-R (5’-CAGGTCATCCTGTGCTCAGTT-3’),
CYP2D6-probe (5’-FAM GCTGGATG 3’DQ); CYP3A4-F
(5’-GATGGCTCTCATCCCAGACTT-3’), CYP3A4-R
(5’AGTCCATGTGAATGGGTTCC-3’), CYP3A4-probe
(5’-FAM TCCTCCTG 3’DQ); CYP3A5-F (5’-TGCCCAG-
TATGGAGATGTATTG-3’), CYP3A5-R (5’-GCTGTAGG
CCCCAAAGATG-3’), CYP3A5-probe (5’-FAM GGAAG-
CAG 3’DQ); PGK1-F (5’-GGAGAACCTCCGCTTTCAT-
3’), PGK1-R (5’-CTGGCTCGGCTTTAACCTT-3’),
PGK1-probe (5’-FAM GGAGGAAG 3’DQ); RPL13-F (5’-
ACAGCTGCTCAGCTTCACCT-3’), RPL13-R (5’-TGGC
AGCATGCCATAAATAG-3’), RPL13-probe (5’-FAM-
CAGTGGCA3’DQ); HPRT-F (5’-TGACCTTGATT-
TATTTTGCATACC-3’), HPRT-R (5’CGAGCAAGACG
TTCAGTCCT-3’), HPRT-probe (5’-FAM GCTGAGGA
3’DQ).
The amplification protocol consisted of 15 min at 95°C
followed by 40 cycles at 94°C for 20 s and at 60°C for 1 min.
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The relative transcript quantification was calculated
using the geNorm algorithm for Microsoft Excel™ after
normalization by expression of the control genes [phos-
phoglycerate kinase1 (PGK1), ribosomal protein L13
(RPL13) and hypoxanthine-guanine-phosphoribosyltrans-
ferase (HPRT)] and expressed in arbitrary units (a.u.).
EROD assay
The CYP1A1 ethoxyresorufin-O-deethylase activity
(EROD) was determined in intact cells as described by
Kennedy and Jones [24] with 5 μM ethoxyresorufin in
growth medium as substrate in the presence of 1.5 mM
salicylamide, to inhibit conjugating enzymes. The assay
was performed at 37°C. The fluorescence of resorufin gen-
erated by the conversion of ethoxyresorufin by CYP1A1
was measured first, immediately after addition of reagents
and then every 10 min for 60 min at 37°C in a Tecan infi-
nite 200 fluorescence plate reader with excitation of
530 nm and emission at 595 nm. A standard curve was
constructed using resorufin.
RNA interference assay
Cells were transfected with Invitrogen Stealth™ siRNA
against CYP1A1 (1:1:1 mixture of #102535, #102537 and
#175787) or scramble negative control (1:1:1 mixture of
#12935-200, #12935-300 and #12935-400) with a final
concentration of 30 nM. The transfection was carried
out according to the Invitrogen forward transfection
protocol for Lipofectamine™ RNAiMAX transfection
reagent. After 48 h of transfection, the transfection med-
ium was aspirated and replaced with exposure medium.
Statistical analysis
The statistical analyses were carried out using GraphPad
Prism version 5.00 software (GraphPad Software Inc.,
San Diego, CA). Results are expressed as mean values ±
standard deviations (SD) for the indicated number of
independent measurements. Differences between the
mean values recorded for different experimental condi-
tions were evaluated by Student’s t-test, and P values are
indicated where appropriate in the figures and in their
legends. A P value < 0.05 was considered as significant.
Results
Intracellular and extracellular levels of gefitinib in
sensitive and resistant NSCLC cell lines
In the first part of the study we evaluated the accumula-
tion kinetics of 0.1 μM radiolabeled gefitinib in H322-
sensitive and H1299-resistant cell lines during 24 h of
treatment. Figure 1A shows a progressive decrease of
the level of intracellular radiolabeled gefitinib only in
the sensitive cell line. The decrease was detectable start-
ing from 6 h of treatment, reaching a minimum level
after 16 h. Similar results were obtained with a higher
(1 μM) gefitinib concentration (not shown).
We then analyzed the effect of the intracellular gefitinib
level on EGFR autophosphorylation in H322 cells. As
reported in Figure 1B after 0.5 h, gefitinib inhibited EGFR
autophosphorylation by around 50% and 80% at doses of
0.1 μM and 1 μM respectively; after 24 h these inhibitions
were significantly reduced indicating a correlation between
the intracellular gefitinib level and the inhibition of EGFR
phosphorylation, confirming our previous results [9].
In an attempt to investigate whether the fall in intra-
cellular gefitinib could be related to a lower influx, an
enhanced efflux or metabolism of the drug, we firstly
measured 5 min of [3H]gefitinib uptake in H322 cells
treated with gefitinib for 0.5 h and 24 h (Figure 1C) and
the level of intracellular gefitinib in the presence of inhi-
bitors of specific efflux transporters (Figure 1D). As
shown in Figure 1C, the initial rate of [3H]gefitinib
uptake at 0.5 h and at 24 h was similar, suggesting that
in the presence of an extracellular fixed concentration
of drug, its influx is constant over time. Since it has
been reported that gefitinib interacts with ABCG2 and
to a lesser extent with ABCB1 [25], the intracellular
levels of the radiolabeled drug were determined after
dosing cells with the respective inhibitors Fumitremor-
gin C (Sigma Aldrich) and PSC833 (kindly provided by
Novartis). We demonstrated only a slight increase in
gefitinib content at 24 h in the presence of Fumitremor-
gin C (inhibition of ABCG2), whereas the inhibition of
ABCB1 pump was ineffective (Figure 1D).
We then analyzed the distribution of radioactivity
among intracellular, extracellular and macromolecule-
linked compartments in another sensitive, EGFR wild-
type cell line (Calu-3) and in resistant H1299 after 0.5 h
and 24 h of treatment with radiolabeled gefitinib. As
shown in Figure 2A, Calu-3 showed a significant drop
in intracellular radioactivity, with a parallel increase in
extracellular radioactivity after 24 h of incubation; by
contrast, the radioactivity distribution was unchanged
between 0.5 h and 24 h in H1299 cells. The amount of
radioactivity in the NaOH fraction (macromolecule-
linked) was less than 10% in both cell lines.
Since the measured radioactivity may be associated, at
least in part, with gefitinib metabolites, the actual
amount of gefitinib was monitored intracellularly and in
the medium by LC-MS/MS after 0.5 h and 24 h of treat-
ment in a panel of NSCLC cell lines showing either sen-
sitivity (H322, H292, Calu-3) or resistance (H460,
H1299, A549, Calu-1, SKLU-1) to the drug.
As shown in Figure 2B, the intracellular level of gefiti-
nib was markedly reduced at 24 h (more than 80%) in
all the sensitive cell lines, whereas the resistant ones
showed a slight reduction (lower than 20%). Figure 2C
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shows that in sensitive cell lines, the extracellular level
of gefitinib after 24 h of treatment was markedly
reduced indicating that the increased radioactivity in the
medium at 24 h (Figure 2A) was not due to gefitinib
itself but to radiolabeled molecules probably derived
from intracellular metabolism of gefitinib and then
extruded into the extracellular compartment.
Taken together these results clearly demonstrate that the
observed decrease in gefitinib content evident only in sensi-
tive cells was due to a high rates of gefitinib metabolism.
Production of gefitinib metabolites by NSCLC cell lines
and their effect on cell growth and EGFR
autophosphorylation
Employing the standards kindly provided by AstraZe-
neca, we analyzed the appearance of the three main
gefitinib metabolites (M1; M2; M3) inside and outside
the cells after 0.5, 6 and 24 h of treatment with 0.1 μM
gefitinib.
LC-MS/MS analysis (Figure 3A) showed that the M1
metabolite was present at a very low level in the intra-
cellular compartment, mainly in sensitive cell lines,
whereas M2 and M3 were undetectable.
The M1 metabolite was also present in the extracellu-
lar compartment (Figure 3B) at concentrations between
0.01 and 0.05 μM only in sensitive cell lines.
We then tested on sensitive and resistant cell lines
whether metabolites M1, M2 and M3, when present in
the growth medium at concentrations equivalent to gefi-
tinib, were able to exert similar biological effects than
gefitinib. As shown in Figure 3C, gefitinib and its meta-
bolites inhibited, in a dose-dependent manner, cell
Figure 1 Intracellular content of gefitinib in NSCLC cell lines and its effect on EGFR autophosphorylation. A) Time course of 0.1 μM [3H]
gefitinib accumulation in H322 (●) and H1299 (○) cell lines. Each point represents the mean ± SD of four independent determinations. B) H322 cells
were incubated for 0.5 h and 24 h with the indicated extracellular concentrations of gefitinib before stimulation with 0.1 μg/ml EGF for 5 min. Western
blot analysis was performed by using monoclonal antibodies directed to p-EGFR(p-Tyr1068) and to EGFR. The immunoreactive spots were quantified
by densitometric analysis, ratios of phosphotyrosine/total EGFR were calculated and values are expressed as percentage of inhibition versus control.
The experiment, repeated three times, yielded similar results. C) H322 cells were incubated with 0.1 μM gefitinib for 0.5 h or 24 h and then the initial
rate (5 min) of 0.1 μM [3H]gefitinib uptake was measured. Each bar represents the mean ± SD of four independent determinations. D) H322 cells were
exposed to 0.1 μM [3H]gefitinib for 0.5 h and 24 h, in the absence or in the presence of 10 μM Fumetrimorgin C (F) or PSC833 (P) and then
intracellular gefitinib content was determined. Values given are the means (± SD) of three independent determinations (***P < 0.001).
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Figure 2 Intracellular and extracellular level of gefitinib in NSCLC cell lines. A) Radioactivity distribution in Calu-3 and H1299 cells
incubated with 0.1 μM [3H]gefitinib for 0.5 h or 24 h. The amount of radioactivity was determined in intracellular (gray), extracellular (white) and
intracellular macromolecule-linked (black) compartments. Values are given as percentage versus the total amount of radioactivity. B) Intracellular
level and C) extracellular concentration of gefitinib in a panel of NSCLC cell lines evaluated by LC-MS/MS. Gefitinib-sensitive cell lines (H322,
H292, Calu-3) and resistant-cell lines (H460, H1299, A549, Calu-1, SKLU-1) were incubated with 0.1 μM gefitinib for 0.5 h and 24 h. Values given
are the means (± SD) of four independent determinations (**P < 0.01; ***P < 0.001).
Alfieri et al. Molecular Cancer 2011, 10:143
http://www.molecular-cancer.com/content/10/1/143
Page 6 of 14
proliferation in sensitive H322 cells with IC50 values of
0.13, 0.7, 0.5 and 1.4 μM for gefitinib, M1, M2 and M3
respectively. Figure 3D shows that gefitinib and metabo-
lites inhibited with the same potency EGFR autopho-
sphorylation. These results were further confirmed in
both Calu-3 and H292 cell lines.
It should be noted that metabolites were only effective
in all the resistant cells at very high concentrations
(IC50 > 20 μM) (see Figure 3E for H1299) indicating
that the metabolites themselves did not have an additive
toxic effect (IC50 for gefitinib 9 μM).
Effect of gefitinib on CYP mRNAs expression and EROD
activity in NSCLC cell lines
The baseline transcript levels of CYP1A1, CYP1A2,
CYP2D6, CYP3A4 and CYP3A5 were determined in
both sensitive and resistant cell lines by RT-PCR and
data are summarized in Figure 4A. CYP1A1 and
CYP1A2 were expressed at significant levels only in
H322, H292 and Calu-3 cell lines, CYP2D6 was detected
in all cell lines, whereas CYP3A4 was undetected.
CYP3A5 was present at high level only in A549 cells.
The inducibility of individual CYP genes by gefitinib
was then investigated and the levels of CYP1A1,
CYP1A2, CYP2D6 and CYP3A5 mRNAs were assessed
after treating cells with the drug. After 6 h, significantly
higher gene expression levels of CYP1A1 and CYP1A2
were observed in all sensitive cell lines. By contrast no
significant modulation of gene expression was observed
in resistant cell lines (Figure 4B).
In order to evaluate whether modulation of the
CYP1A1 transcript levels was associated with changes in
the respective enzyme activity levels, we measured the
activity of 7-ethoxyresorufin-O-deethylase (EROD), a
commonly-used indicator of CYP1A activity [26], both
basally and after exposure of cells to gefitinib.
Figure 3 Production and biological activity of gefitinib metabolites. Cells were incubated with 0.1 μM gefitinib for 0.5, 6 or 24 h and then
the M1 content was determined both in the intracellular (A) and extracellular (B) compartment, through LC-MS/MS analysis. M1 levels calculated
for each cell line were expressed as pmol/mg of protein (intracellular) or μM (extracellular). Values given are the means (± SD) of three
independent determinations C) H322 cells were exposed for 72 h to different concentrations of gefitinib or its metabolites (ranging from 0.05 to
10 μM) and then cell growth was assessed using crystal violet staining. Data are expressed as percent inhibition of cell proliferation versus
control cells. The mean values of three independent measurements (± SD) are shown. D) H322 cells were incubated for 0.5 h with the indicated
concentrations of gefitinib and metabolites, before stimulation with 0.1 μg/ml EGF for 5 min. Western blot analysis was performed by using
monoclonal antibodies directed to p-EGFR(p-Tyr1068) and to EGFR. The immunoreactive spots at each point were quantified by densitometric
analysis, ratios of phosphotyrosine/total EGFR were calculated and values expressed as percentage of inhibition versus control. The experiment,
repeated three times, yielded similar results. E) H1299 cells were exposed for 72 h to different concentrations of gefitinib or its metabolites
(ranging from 1 to 30 μM) and then cell growth was assessed using crystal violet staining. Data are expressed as percent inhibition of cell
proliferation versus control cells. The mean values of three independent measurements (± SD) are shown.
Alfieri et al. Molecular Cancer 2011, 10:143
http://www.molecular-cancer.com/content/10/1/143
Page 7 of 14
In untreated cells, EROD activity was detectable only in
sensitive cells, and gefitinib caused a significant increase in
this activity (3-6 fold induction) with a maximum at 16-24
h (Figure 5A). Although both CYP1A1 and CYP1A2 carry
out EROD activity, the 1A1 form has a much higher speci-
fic EROD activity than 1A2 [27]. A further demonstration
of CYP1A1 involvement came from the use of 10 μM a-
NAP, a CYP1A1 inhibitor [28,29] or from CYP1A1 silen-
cing using siRNAs that significantly inhibited both base-
line and gefitinib-induced EROD activity (Figure 5B).
We then tested the effect of other EGFR inhibitors
(erlotinib, cetuximab, lapatinib) and of inhibitors of
MAPK and PI3K/AKT/mTOR signalling transduction
pathways on EROD activity in H322 cell line. As shown
in Figure 5C erlotinib, cetuximab and lapatinib induced
a significant increase in EROD activity comparable to
that induced by gefitinib.
Both MEK inhibitors (PD98059 and U0126) strongly
activated CYP1A1 activity, in contrast no increase in the
activity was detectable after incubation with the inhibi-
tors of PI3K/AKT/mTOR pathway tested (wortmannin,
PI3K inhibitor; RAD001 mTOR inhibitor; NVP-BEZ235
PI3K and mTOR inhibitor)
Effect of hypoxia, cigarette smoke extract and cell density
on gefitinib metabolism
Since it is known that hypoxia downregulates the expres-
sion and activity of many CYPs including CYP1A1 [30], we
evaluated whether hypoxia could prevent gefitinib metabo-
lism and its intracellular loss. The simultaneous exposure
of H322 cells to gefitinib and hypoxia (Figure 6A) almost
completely prevented gefitinib catabolism inside the cells.
Differently, CYP1A1 activity was strongly induced in Calu-
3 cells exposed to 2.5% cigarette smoke extract (CSE) for
24 h (see inset Figure 6B) and consequently gefitinib con-
sumption (Figure 6B) was significantly expedited.
Moreover, as expected, cell density strongly affected
the reduction in the intracellular level of gefitinib at 24
Figure 4 Effect of gefitinib on CYP mRNAs expression. A) Basal expression of CYP1A1, 1A2, 2D6 and 3A5 mRNAs in NSCLC cell lines was
detected by RT-PCR. The mean values of three independent measurements (± SD) are shown. It is to note that CYP3A4 was undetected. B) The
cells were exposed to 0.1 μM gefitinib for 6 h and then gefitinib induction of CYP1A1, 1A2, 2D6 and 3A5 mRNAs was evaluated by RT-PCR and
expressed as fold induction relative to basal expression. The mean values of three independent measurements (± SD) are shown.
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Figure 5 Effect of gefitinib on EROD activity. A) EROD assay was performed in intact living cells untreated or treated for 24 h with 0.1 μM
gefitinib in the absence or in the presence of 10 μM a-NAP. CYP1A1 activity was measured using 7-ethoxyresorufin as a substrate and
expressed as pmol resorufin/mg protein/min. Values given are the means (± SD) of three independent determinations. It is of note that in the
gefitinib-resistant cells both the basal and the induced EROD activity were undetectable (not shown) (*P < 0.05; **P < 0.01; ***P < 0.001). B)
H322 cells were transfected with siRNA against CYP1A1 or a scrambled negative control with a final concentration of 30 nM for 48 h and then
treated for 16 h with 0.1 μM gefitinib before EROD assay was performed. Values given are the means (± SD) of four independent determinations
(***P < 0.001). C) EROD assay was performed in intact living cells untreated or treated for 24 h with 0.1 μM gefitinib, 0.1 μM erlotinib, 0.1 μM
lapatinib 100 μg/ml cetuximab, 10 μM U0126, 10 μM PD98059, 1 μM Wortmannin, 100 nM RAD001 and 100 nM NVPBEZ235. CYP1A1 activity was
measured using 7-ethoxyresorufin as a substrate and expressed as pmol resorufin/mg protein/min. Values given are the means (± SD) of three
independent determinations. (**P < 0.01; ***P < 0.001).
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h in the Calu-3 line (Figure 6C) and consequently cells
seeded at high and low density but with a similar
growth-rate quotient, exhibited a significant difference
in the sensitivity to gefitinib. Indeed, as shown in Figure
6D, cells at low density showed a 15-fold higher sensi-
tivity to gefitinib (IC50 0.4 μM) as compared to cells at
high density (IC50 6 μM).
Effects of CYP1A1 inhibition on the intracellular level of
gefitinib, EGFR autophosphorylation and inhibition of cell
growth
In an attempt to better characterize the role of CYP1A1
in sensitive cells, we measured the intracellular content
of radiolabeled gefitinib in Calu-3 cells in the presence
of 10 μM a-NAP. This inhibitor almost completely
abolished the fall in intracellular gefitinib levels after 24
h of treatment (Figure 7A) and the intracellular appear-
ance of the M1 metabolite (not shown).
To further demonstrate that a-NAP was able to main-
tain a high level of effective drug, Calu-3 cells were trea-
ted for 24 h with gefitinib in the presence or absence of
a-NAP and then the medium was collected (conditioned
media) and extracts from H322 cells exposed to condi-
tioned media for 2 h were prepared to examine the inhi-
bition of EGFR autophosphorylation by Western blot
analysis. As shown in Figure 7B in H322 cells EGFR
autophosphorylation was unaffected when cells were
treated with gefitinib-conditioned medium collected
Figure 6 Conditions affecting gefitinib metabolism: hypoxia, cigarette smoke extract and cell density. A) H322 cells were incubated with
0.1 μM [3H]gefitinib under normoxia or hypoxia for the indicated times. Values given of gefitinib content, expressed as pmol/mg of protein, are
the means (± SD) of four independent determinations (**P < 0.01; ***P < 0.001). B) Calu-3 cells were treated for 24 h with 2.5% of CSE and then
exposed to 0.1 μM [3H]gefitinib for the indicated times. Values given are the means (± SD) of three independent determinations (**P < 0.01; ***P
< 0.001). Inset: EROD assay performed in cells untreated or treated for 24 h with 1, 2.5 or 5% CSE expressed as pmol Res/mg protein/min. C)
Calu-3 cells were seeded at different cell density (from 7000 to 70000 cells/cm2) and after 24 h incubated for 0.5 h (●) or 24 h (■) with 0.1 μM
[3H]gefitinib. Then, the intracellular [3H]gefitinib content was determined and plotted versus final cell density expressed as μg protein/cm2. Inset:
values are expressed as % of reduction versus 0.5 h value. D) Calu-3 seeded at low and high density (7000 and 70000 cells/cm2 respectively)were
exposed for 72 h to different concentrations of gefitinib. Cell growth was assessed using crystal violet staining. Data are expressed as percent
inhibition of cell proliferation versus control cells. The mean values of three independent measurements (± SD) are shown (*P < 0.05; ***P <
0.001).
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from Calu-3 in the absence of a-NAP, in contrast when
the inhibitor was present in the gefitinib-conditioned
medium, EGFR autophosphorylation was completely
inhibited. These results strongly suggest that in sensitive
cells the metabolites released into the medium (low
amount of M1 and other undetermined compounds)
were ineffective in EGFR inhibition.
The high and constant drug level inside the cells
obtained in the presence of a-NAP maintained a signifi-
cant inhibition of EGFR p44/42 MAPK and AKT phos-
phorylation even after a prolonged period (48 h) of
treatment (Figure 7C) when compared with cells incu-
bated with gefitinib alone.
Sensitive cell lines were then treated with gefitinib in
the presence of 10 μM a-NAP for 72 h in order to
evaluate the effects of CYP1A1 inhibition on efficacy of
gefitinib in inhibiting cell proliferation. In the presence of
the inhibitor the IC50 for gefitinib, evaluated by crystal
violet staining (Figure 7D-F) and confirmed by cell
counting and MTT assay (not shown), was reduced 15, 3
and 6 times in Calu-3, H322 and H292 cells respectively.
Overall, these results show that inhibition of CYP1A1
is associated with reduced gefitinib metabolism,
increased intracellular gefitinib content and increased
drug efficacy in cultured NSCLC cells.
Discussion
The cytochrome P450 system consists of a large number
of enzyme subfamilies involved in the oxidative metabo-
lism of xenobiotics including drugs. They are expressed
Figure 7 Effects of CYP1A1 inhibition on intracellular level of gefitinib, EGFR autophosphorylation and inhibition of cell growth. A)
Calu-3 cells were incubated with 0.1 μM [3H]gefitinib for 0.5, 24, 48 or 72 h in the absence or in the presence of 10 μM a-NAP. Values given of
gefitinib content, expressed as pmol/mg of protein, are the means (± SD) of four independent determinations. a-NAP was renewed after 36 h of
gefitinib treatment. (***P < 0.001). B) Calu-3 cells were treated with 0.1 μM gefitinib for 24 h in the absence or in the presence of 10 μM a-NAP,
then the conditioned media (CM) were collected and extracts were prepared from H322 cells exposed for 2 h to CM. The effect of CM on EGF
(0.1 μg/ml for 5 min)-induced EGFR autophosphorylation was examined by Western blotting using monoclonal antibodies directed against
pEGFR(Tyr1068) and actin. The experiment, repeated twice, yielded similar results. Line 1: CM from control cells; line 2: CM from gefitinib treated
cells; line 3: CM from a-NAP treated cells; line 4: CM from a-NAP and gefitinib treated cells. C) H322 and Calu-3 cells were incubated for 48 h
with 0.1 μM gefitinib in the absence or in the presence of 10 μM a-NAP. Before protein extraction cells were stimulated with 0.1 μg/ml EGF for
5 min. Western blot analysis was performed by using monoclonal antibodies directed against pEGFR(Tyr1068), EGFR, p-p44/42 MAPK, p44/42
MAPK, pAKT (Ser473), AKT. The experiment, repeated three times, yielded similar results. a-NAP was renewed after 24 h of gefitinib treatment. D)
Calu-3, (E) H322, (F) H292 were exposed for 72 h to different concentrations of gefitinib in the absence or in the presence of 10 μM a-NAP. Cell
growth was assessed using crystal violet staining as described in Materials and Methods. Data are expressed as percent inhibition of cell
proliferation versus control cells. The mean values of three independent measurements (± SD) are shown. a-NAP was renewed after 36 h of
gefitinib treatment (*P < 0.05; **P < 0.01; ***P < 0.001).
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mainly in the liver, but extra-hepatic expression of a
number of these enzymes does occur [31]. Although the
primary site of gefitinib metabolism is the liver, tumor
cell metabolism can significantly affect treatment effec-
tiveness. However, to our knowledge, no studies have
been performed addressing gefitinib metabolism in lung
tumor cells.
The present study shows that the drop in gefitinib con-
tent observed in EGFR wild-type gefitinib-sensitive cell
lines after 24 h of treatment was mainly due to gefitinib
metabolism by CYP1A1 activity and not related to a time-
dependent modification of influx or efflux processes. Our
results indicate that there is a significant difference
between gefitinib-sensitive and -resistant cell lines with
regard to drug metabolism. Surprisingly, only sensitive
cells were able to metabolize gefitinib and as a conse-
quence, after 24 h of treatment, gefitinib disappeared both
inside and outside the cells. The majority of radiolabeled
gefitinib metabolites were present in the extracellular
compartment as not well defined metabolites since we
could barely detect the M1 metabolite and M2 or M3
were undetectable. In any case the metabolites present in
the medium were not effective in inhibiting EGFR autop-
hosphorylation as demonstrated by the conditioned med-
ium experiment.
It has been reported that both gefitinib and its des-
methyl metabolite (M3) formed through CYP2D6, inhib-
ited with a similar potency and selectivity subcellular
EGFR tyrosine kinase activity [32]. However, M3 was 15
times less active in a cell-based assay and consequently
it was assumed that this metabolite was unlikely to con-
tribute to the activity of gefitinib in vivo due to poor
cell penetration.
On the contrary, when metabolites M1, M2 and M3
were tested in our responsive cell models at concentra-
tions equivalent to that of gefitinib, they exhibited a signif-
icant inhibition of EGFR autophosphorylation and
proliferation in intact cells, indicating their ability to enter
cells and to interact with the catalytic domain of EGFR.
Finally, in gefitinib resistant cell lines M1, M2 and M3
metabolites were poorly effective (IC50 > 20 μM in prolif-
eration assay) indicating that at least these metabolites did
not produce additive toxic effects in NSCLC cell lines.
In contrast to its abundant hepatic expression,
CYP3A4 seems to play a minor role in lung metabolism,
being expressed in only about 20% of cases [33]. Real-
time PCR analysis confirmed the lack of expression of
this isoform in our NSCLC cell models, as reported for
A549 cells [34]. CYP2D6 was detected in all cell lines,
whereas both CYP1A1 and CYP1A2 were expressed at
significant levels in sensitive cells. Inducibility of
CYP1A1 and CYP1A2 transcripts by gefitinib was clearly
demonstrated in sensitive cell lines, while induction of
CYP1A1 mRNA was not detected in resistant cell lines.
EROD activity demonstrated a 3-6 fold induction of
CYP1A1 elicited by gefitinib in sensitive cells. To the
best of our knowledge, this is the first time that the
induction by gefitinib of relevant metabolic enzyme(s)
has been demonstrated.
The reason why gefitinib induces CYP expression and
activity only in sensitive cells could be ascribed to the
ability of gefitinib to inhibit signal transduction pathway
downstream EGFR. It has been recently demonstrated
that EGF represses the dioxin-mediated induction of
CYP1A1 in normal human keratinocytes preventing
recruitment of the p300 coactivator [35]. Therefore,
EGFR signalling is a repressor of the aryl hydrocarbon
receptor and regulates the transcription of numerous
genes including CYP1A1. In this context, EGFR inhibi-
tors such as gefitinib, erlotinib, lapatinib or cetuximab
might affect the induction of CYP1A1 in those cell types
in which the drug effectively inhibits signalling controlled
by EGFR. The inhibition of MAPK pathway might repre-
sent a link between EGFR inhibition and CYP1A1 induc-
tion since PD98059 and U0126, well known MEK1/2
inhibitors, induced CYP1A1 activity as did gefitinib in
H322 cells, while none of PI3K/AKT/mTOR inhibitors
tested was effective. It is noteworthy that constitutive
activation of signaling pathways downstream of EGFR is
a recognized mechanism or resistance against reversible
EGFR tyrosine kinase inhibitors [5].
We surmise that gefitinib metabolism is a conse-
quence and not the cause of drug responsiveness and
might be useful for early evaluation of response to gefiti-
nib in tumor lacking activating mutations.
Since CYP1A1 inducibility strongly correlates with
CYP1A1 gene polymorphism [36] we also tested the
genotypic asset of our cell lines regarding the two main
polymorphic forms of CYP1A1 (CYP1A1*2A and
CYP1A1*2C). All the tested cell lines carried a wild type
homozygous genotype for both the polymorphisms and
so we can exclude that different genotypes are involved
in the different capability of metabolizing gefitinib.
The role of CYP1A1 polymorphism as a predictor of
clinical outcome to EGFR-TKIs in patients with
advanced lung cancer has very recently been reported
[37]. The authors note that CYP1A1*2A polymorphism
correlates with the response to EGFR-TKIs of NSCLC,
wild type T/T patients having an improved response of
inhibitors versus T/C and C/C alleles.
Studies have shown that the hepatic metabolism of
gefitinib is primarily catalyzed via CYP3A4, conse-
quently the effects of known inducers (phenytoin, carba-
mezepine, rifampicin) and inhibitors (ketoconazole,
itraconazole, erythromycin and claritromycin) of
CYP3A4 activity have been investigated [6].
Our results indicate that, in NSCLC cells metabolizing
gefitinib, CYP1A1 inhibition could lead to increased
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local exposure to the active drug. In fact, inhibition by
a-naphthoflavone was associated with lower gefitinib
metabolism and consequently with a prolonged expo-
sure to locally active drug. This leads to enhanced inhi-
bition of EGFR, MAPK and AKT phosphorylation and
cell proliferation, with the result of reduced IC50 for
gefitinib in proliferation assays of EGFR wild-type
NSCLC cell lines.
From a medicinal chemistry perspective, these results
stress the importance of considering drug pharmacoki-
netics at the intratumoral cellular level, focusing on the
roles of transport and metabolism in the target cells.
While the structure of gefitinib makes it a substrate of
transporters [9], thus enhancing its activity toward intra-
cellular targets, it also harbors metabolic liabilities in
tumor cells. From this point of view, its interaction with
CYP3A4 seems mainly related to total-body exposure gefi-
tinib, while CYP1A1 is mainly responsible of its metabo-
lism in tumor cells. A program of structural optimization
should thus consider the effects of structure modulation
on all these processes in combination.
In addition, a strategy of increasing gefitinib activity
by using specific CYP inhibitors, could be pursued in
the context of optimizing the use of gefitinib for the
treatment of EGFR wild-type gefitinib-sensitive tumors.
Interstitial lung disease (ILD) has been reported as a
serious adverse effect of gefitinib treatment [38]. The
incidence of acute ILD during gefitinib treatment varies
between different ethnic groups occurring more fre-
quently in Japanese patients (4%-6%) than in Caucasian
(0.2-0.3%) [39]. Although the precise mechanism of ILD
induced by gefitinib remains unknown, it has been pro-
posed that bioactivation of gefitinib by CYP1A1 in the
lung may be related to the risk of developing ILD
mainly in smokers [8]. In this context the optimisation
of CYP1A1 inhibition may not only improve gefitinib
efficacy but even reduce the incidence of ILD.
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